Tyrosine kinase inhibitors (TKIs) are orally active, small molecules that exhibit antitumor activity by targeting enzymes that play a critical role cellular functions, including modulation of growth factor signaling, proliferation, carcinogenesis, and cell differentiation. Several TKIs, including sorafenib and regorafenib, have already been approved for first and second line treatment of hepatocellular carcinoma (HCC), respectively. Further, a plethora of novel TKIs such as lenvatinib and cabozantinib are being investigated for their potential use in the therapeutic management of HCC. In this whiteboard video, Dr. Richard S. Finn of the UCLA Geffen School of Medicine discusses the management of adverse events related to this class of agents.
Earn CME Credit for this activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=7285
© 2018 Imedex, LLC.